Ravicti® (glycerol phenylbutyrate) approved by the National Administration of Drugs, Food and Medical Devices in Argentina for treatment of urea cycle disorders
Stockholm, September 29, 2023 – Immedica and its partner Innovative Medicines AS announces that the National Administration of Drugs, Food and Medical Devices (ANMAT) in Argentina has granted marketing authorization for Ravicti® (glycerol phenylbutyrate) for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), Citrullinemia type 1, argininosuccinuria, argininemia and hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein